<DOC>
	<DOCNO>NCT00812318</DOCNO>
	<brief_summary>To evaluate single dose relative bioavailability GSK1265744 10mg administer either oral solution fast , two 5mg tablet fast , two 5mg tablet follow moderate meal .</brief_summary>
	<brief_title>Healthy Volunteer Study To Assess The Bioavailability GSK1265744 When Administered Orally Either When Fasted Following Meal .</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>Healthy determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test 12lead ECG . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male female 18 55 year age . A female subject eligible participate nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) include female : Is premenopausal documented bilateral tubal ligation , bilateral oophorectomy ( removal ovary ) hysterectomy , Is postmenopausal defined 12 month spontaneous amenorrhea . A follicle stimulate hormone ( FSH ) level perform confirm postmenopausal status . For study , FSH level &gt; 40 mlU/ml confirmatory . A male eligible enter participate study surgically sterile OR either agree abstain sexual intercourse female partner agree use condom/spermicide , addition female partner use another form contraception outline Section 7.1 . Body weight &gt; = 50 kg ( 110 lb . ) men &gt; = 45 kg ( 99 lb ) woman body mass index ( BMI ) within range 18.531.0 kg/m2 ( inclusive ) . A signed date write informed consent obtain subject subject 's legal representative prior screen . Subject must capable give write informed consent , include compliance requirement restriction list consent form . As result medical interview , physical examination , screen investigation , Investigator considers subject unfit study . Has positive prestudy Hepatitis B surface antigen ; positive hepatitis C ( HCV ) antibody detectable HCV ribonucleic acid ( RNA ) ; positive HIV1 antibody result . Has history regular alcohol consumption average &gt; 7 drinks/week woman &gt; 14 drinks/week men within 6 month screen visit . Note : 1 drink equivalent 12 g alcohol = 5 ounce ( 150 ml ) wine 12 ounce ( 360 ml ) beer 1.5 ounce ( 45 ml ) 80 proof distil spirit . Unwilling abstain alcohol 48 hour prior start dose collection final pharmacokinetic sample treatment period . Unwilling refrain use illicit drug adhere protocolstated restriction participate study . The subject receive investigational drug participate research trial within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication . Participation study would result donation blood excess 500 mL within 56 day period . Note : This include plasma donation . History presence allergy intolerance study drug component drug class , history drug allergy , opinion physician responsible , contraindicate participation . In addition , heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol . Note : `` Study '' `` investigational '' drug include GSK1265744 placebo . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy exclude . Exclusion criterion screen ECG per protocol The subject 's systolic blood pressure outside range 90140mmHg , diastolic blood pressure outside range 4590mmHg heart rate outside range 50100bpm female subject 45100 bpm male subject . Has history regular use tobacco nicotinecontaining product within 3 month screen visit . The subject positive prestudy drug and/or alcohol screen . Use prescription nonprescription drug , include antacid , vitamin , herbal dietary supplement ( include St John 's Wort iron supplement ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator sponsor medication interfere study procedure compromise subject safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>HIV infect subject</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>GSK1265744 .</keyword>
</DOC>